CVKD

6.32

4.39% -0.29

Pre-mercato: 6.88 0.56 +8.86%

Cadrenal Therapeutics Inc (CVKD)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione

Precedente Chiudi:

$6.61

Aprire:

$6.61

Volume 24 ore:

102.93K

Relative Volume:

1.96

Capitalizzazione di mercato:

$19.45M

Reddito:

Utile/perdita netta:

$-13.24M

Rapporto P/E:

-0.9461

EPS:

-6.6801

Flusso di cassa netto:

$-12.61M

1 W Prestazione:

+18.57%

1M Prestazione:

+34.47%

6M Prestazione:

-50.43%

1 anno Prestazione:

-61.32%

Intervallo 1D:

$6.10

$6.74

Intervallo di 1 settimana:

$5.35

$7.27

Portata 52W:

$4.21

$16.50

Cadrenal Therapeutics Inc Stock (CVKD) Company Profile

Nome

Cadrenal Therapeutics Inc

Settore

Healthcare (1106)

Industria

Biotechnology (615)

Telefono

904-300-0701

Indirizzo

822 A1A NORTH, PONTE VEDRA

Dipendente

Cinguettio

Prossima data di guadagno

2026-05-14

Ultimi documenti SEC

CVKD's Discussions on Twitter

Compare CVKD vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CVKD Cadrenal Therapeutics Inc	6.32	19.45M	0	-13.24M	-12.61M	-6.6801
VRTX Vertex Pharmaceuticals Inc	424.36	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.06B	5.36B	287.73M	924.18M	2.5229

Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-12-18	Iniziato	Noble Capital Markets	Outperform

Cadrenal Therapeutics Inc Borsa (CVKD) Ultime notizie

May 05, 2026

CVKD stock retail sentiment peaks after FDA clears phase 3 path for blood clot drug - MSN

May 05, 2026

May 01, 2026

CVKD Earnings History & Surprises | EPS & Revenue Results | CADRENAL THERAPEUTICS INC (NASDAQ:CVKD) - ChartMill

May 01, 2026

Apr 30, 2026

Cadrenal Therapeutics completes CAD-1005 End-of-Phase 2 meeting with FDA - TipRanks

Apr 30, 2026

Cadrenal Therapeutics Receives FDA Guidance for Pivotal Phase 3 Trial of CAD-1005 in Heparin-Induced Thrombocytopenia (HIT) - Minichart

Apr 30, 2026

Cadrenal Advances CAD-1005 Into FDA-Guided Phase 3 Trial - TipRanks

Apr 30, 2026

Cadrenal receives FDA guidance to advance CAD-1005 to phase 3 trial - Investing.com

Apr 30, 2026

Cadrenal Therapeutics advances CAD-1005 to pivotal Phase 3 after FDA End-of-Phase 2 meeting - TradingView

Apr 30, 2026

FDA backs CAD-1005 Phase 3 HIT trial path at Cadrenal (NASDAQ: CVKD) - Stock Titan

Apr 30, 2026

Cadrenal Therapeutics Announces End-Of-Phase 2 Meeting with the Fda and Pivotal Phase 3 Registration Path for Cad-1005 in Heparin-Induced Thrombocytopenia - marketscreener.com

Apr 30, 2026

[EFFECT] Cadrenal Therapeutics, Inc. SEC Filing - Stock Titan

Apr 30, 2026

Apr 29, 2026

Cadrenal Therapeutics (CVKD) registers 1.18M shares for resale under S-3 - Stock Titan

Apr 29, 2026

Apr 26, 2026

Understanding the Setup: (CVKD) and Scalable Risk - Stock Traders Daily

Apr 26, 2026

symbol__ Stock Quote Price and Forecast - CNN

Apr 26, 2026

Apr 21, 2026

Cadrenal Therapeutics Incprospectus filed for resale of up to 1.2 million shares of common stock by selling stockholders- SEC filing - marketscreener.com

Apr 21, 2026

Apr 20, 2026

Analysts Adjust Cadrenal Therapeutics, Inc. (CVKD) Valuation After Including CAD-1005 Program - Insider Monkey

Apr 20, 2026

1.18M shares registered for resale; Cadrenal Therapeutics (NASDAQ: CVKD) - Stock Titan

Apr 20, 2026

Apr 19, 2026

5 Oversold Biotech Stocks to Invest In Now - Insider Monkey

Apr 19, 2026

Apr 14, 2026

CVKD Technical Analysis | Trend, Signals & Chart Patterns | CADRENAL THERAPEUTICS INC (NASDAQ:CVKD) - ChartMill

Apr 14, 2026

Apr 13, 2026

Retail Surge: What is the next catalyst for Cadrenal Therapeutics IncWeekly Stock Recap & Reliable Price Action Trade Plans - baoquankhu1.vn

Apr 13, 2026

Apr 12, 2026

FDA Review Uncertainty Puts Cadrenal Therapeutics’ CAD-1005 Phase 3 Timeline and Costs at Risk - TipRanks

Apr 12, 2026

Earnings Beat: Can Cadrenal Therapeutics Inc stock double in the next year - baoquankhu1.vn

Apr 12, 2026

Apr 11, 2026

Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting - ADVFN

Apr 11, 2026

Apr 10, 2026

Is Cadrenal (CVKD) Stock Good for Active Traders | Price at $4.96, Down 0.20%Viral Momentum Stocks - Cổng thông tin điện tử tỉnh Lào Cai

Apr 10, 2026

Apr 09, 2026

Is Cadrenal (CVKD) Stock trading below intrinsic value | Price at $4.86, Up 0.21%Analyst Downgrade - Cổng thông tin điện tử tỉnh Lào Cai

Apr 09, 2026

Apr 08, 2026

CVKD: Results Show 12-LOX Inhibition Targets Inflammation from Obesity and Type 2 Diabetes - Yahoo Finance

Apr 08, 2026

How does Cadrenal (CVKD) Stock perform in rallies | Price at $4.32, Down 7.10%Real Trader Insights - Cổng thông tin điện tử Tỉnh Sơn La

Apr 08, 2026

Apr 07, 2026

CVKD: Analyst Maintains Buy Rating, But Lowers Price Target | CV - GuruFocus

Apr 07, 2026

Cadrenal Therapeutics price target lowered to $13 from $32 at H.C. Wainwright - TipRanks

Apr 07, 2026

Apr 06, 2026

Is Cadrenal (CVKD) Stock Breaking Support | Price at $4.65, Down 1.06%Trend Signals - Cổng thông tin điện tử Tỉnh Sơn La

Apr 06, 2026

Apr 03, 2026

CVKD Stock Analysis: Cadrenal Therapeutics Inc. 4.08% Dip to $4.7 Performance Recap - Xã Thanh Hà

Apr 03, 2026

Apr 02, 2026